



HAL
open science

Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-(E)-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs

Tuniyazi Abuduaini, Vincent Roy, Julien Marlet, Catherine Gaudy-Graffin, Denys Brand, Cécile Baronti, Franck Touret, Bruno Coutard, Tamara R Mcbrayer, Raymond F Schinazi, et al.

► To cite this version:

Tuniyazi Abuduaini, Vincent Roy, Julien Marlet, Catherine Gaudy-Graffin, Denys Brand, et al.. Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-(E)-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs. *Molecules*, 2021, 26 (5), pp.1493. 10.3390/molecules26051493 . inserm-03412066

HAL Id: inserm-03412066

<https://inserm.hal.science/inserm-03412066>




Submitted on 2 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-(E)-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs

Tuniyazi Abuduaini ¹, Vincent Roy ^{1,*} , Julien Marlet ², Catherine Gaudy-Graffin ², Denys Brand ², Cécile Baronti ³, Franck Touret ³ , Bruno Coutard ³, Tamara R. McBrayer ⁴, Raymond F. Schinazi ⁴ and Luigi A. Agrofoglio ^{1,*} 

¹ Institute of Organic and Analytical Chemistry, CNRS UMR 7311, Université d'Orléans, F-45067 Orléans, France; tuniyazi.abuduaini@univ-orleans.fr

² Inserm U1259, Université de Tours, 37032 Tours, France; julien.marlet@univ-tours.fr (J.M.); catherine.gaudy-graffin@univ-tours.fr (C.G.-G.); denys.brand@univ-tours.fr (D.B.)

³ Unité des Virus Émergents (UVE: Aix-Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection), 13000 Marseille, France; cecile.baronti@univ-amu.fr (C.B.); franck.TOURET@univ-amu.fr (F.T.); bruno.coutard@univ-amu.fr (B.C.)

⁴ Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA 30222, USA; tamara.mcbraze@emory.edu (T.R.M.); rschin@emory.edu (R.F.S.)

* Correspondence: vincent.roy@univ-orleans.fr (V.R.); luigi.agrofoglio@univ-orleans.fr (L.A.A.)



Citation: Abuduaini, T.; Roy, V.; Marlet, J.; Gaudy-Graffin, C.; Brand, D.; Baronti, C.; Touret, F.; Coutard, B.; McBrayer, T.R.; Schinazi, R.F.; et al. Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-(E)-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs. *Molecules* **2021**, *26*, 1493. <https://doi.org/10.3390/molecules26051493>

Academic Editor: Paolo Quadrelli

Received: 16 February 2021

Accepted: 3 March 2021

Published: 9 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: A series of hitherto unknown (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleosides phosphonate prodrugs bearing 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as the key synthetic step. All novel compounds were evaluated for their antiviral activities against HBV, HIV and SARS-CoV-2. Among these molecules, only compound **15j**, a hexadecyloxypropyl (HDP)/(isopropylloxycarbonyl-oxymethyl)-ester (POC) prodrug, showed activity against HBV in Huh7 cell cultures with 62% inhibition at 10 μ M, without significant cytotoxicity (IC_{50} = 66.4 μ M in HepG2 cells, IC_{50} = 43.1 μ M in HepG2 cells) at 10 μ M.

Keywords: nucleosides; olefin cross metathesis; ultrasound; copper-catalyzed azide-alkyne cycloaddition (CuAAC); antiviral properties; HBV; HIV; SARS-CoV-2

1. Introduction

Acyclic nucleoside phosphonates (ANPs), such as (R)-PMPA [9-[9(R)-2-(phosphonomethoxy)propyl]adenine, **1**] and PMEAs [9-[2-(phosphonomethoxy)ethyl]adenine, **2**] discovered by A. Holý and E. De Clercq in 1986, led to a new family of nucleotide analogs which has attracted considerable attention, [1–4]. In order to improve the oral absorption of these phosphonate analogs, ANPs are delivered as prodrugs [*bis*(POC)-PMPA (**3**) or *bis*(POM)-PMEA (**4**)] prodrug moiety [5] has previously focused on acyloxyalkyl-ester (pivaloyloxymethyl, POM) [6,7], or ((isopropylloxycarbonyl-oxymethyl)-ester, POC) [8], alkoxyalkyl groups (hexadecyloxypropyl, HDP) [9], and more recently on phosphonoamides (ProTides) [10,11]. Currently, several ANP prodrugs (alone or in combination) are FDA-approved drugs against DNA and RNA viruses. In our search for antiviral compounds, we have discovered a new class of acyclic nucleoside phosphonates based on a 4-phosphono-but-2-en-1-yl skeleton, with the double bond having *trans* stereochemistry [12–14]. We have shown that this modification allows for the mimicry of the three-dimensional geometry provided by the backbone of PMEAs, PMPAs, and CDVs ((S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine) while maintaining an electronic contribution similar to that brought by the oxygen atom [12]. Our group has published a series of *bis*(POM)-(1,4-disubstituted-1,2,3-triazol)-(E)-but-2'-enyl nucleoside phosphonates [15]. Among them, the

compound **5** exhibits significant potency against human hepatitis C virus (HCV) infections at 10 μM (95% of inhibition) meanwhile our synthesized *bis*(POC)-(E)-2-methyl-but-2-enylguanine **6** (unpublished data) showed antiviral activity against hepatitis B virus (HBV) with an EC_{50} of 8.5 μM without significant cytotoxicity (Figure 1).





Figure 1. Structure of selected acyclic nucleoside phosphonates (ANPs) and target derivatives. PMPA: 2-(phosphonomethoxy)propyladenine; PMEA: 9-(2-(phosphonomethoxy)ethyl) adenine; POM: pivaloyloxymethyl; POC: (isopropylloxycarbonyl-oxymethyl)-ester.

For nucleosides, it appears that chemical alterations (such as a methyl group at 2' position) at the sugar (or acyclic side-chain) moiety or at the heterocycle such as 1,2,3-triazoles [16] often lead to marked differences in antiviral activity. Based on these findings and on our data for compounds **5** and **6**, we were interested in the synthesis of hitherto unknown (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleosides phosphonate prodrugs and we wish to compare the impact of bis(POC) with the mixed HDP/POC biolabile moiety on the antiviral activity. All compounds were evaluated against hepatitis B virus (HBV), human immunodeficiency virus (HIV-1) and the newly detected severe acute respiratory syndrome (SARS-CoV-2).

2. Results and Discussions

2.1. Chemistry

First, we synthesized the *bis*(POC)allylphosphonate **7** from dimethylallylphosphonate according our previously reported method [14]. Then, optimized olefin cross-metathesis reaction between **7** and 2-methylprop-2-en-1-ol (**8**) was performed in dry dichloromethane with a Hoveyda–Grubbs catalyst (15 mol%) under ultrasonic irradiation at 55 $^{\circ}\text{C}$ during 24 h [17], (Scheme 1). The desired compound **9** was obtained in an excellent 94% yield with only *E*-isomer; no trace of *Z*-isomer was detected (NOESY NMR, see Supplementary Materials). Compound **9** was converted to the corresponding mesylate and the obtained sulfone was used directly in the next step without further purification. The introduction of the azido group on the mesylated compound was realized with sodium azide in DMF at room temperature for 5 h to afford compound **10** in excellent 93% yield.



Scheme 1. Reagents and conditions: (a) Hoveyda–Grubbs catalyst (15 mol%), dry CH_2Cl_2 , 55 $^{\circ}\text{C}$, 24 h, 94%; (b) (i) MsCl , Et_3N , dry CH_2Cl_2 , 0 $^{\circ}\text{C}$ to room temperature (rt), 40 min; (ii) NaN_3 , DMF, rt, 5 h, 93%.


Compound **10** was engaged in a regioselective copper-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) [18,19] with seventeen various terminal alkynes (dipolarophiles) selected to bear bulky, polar and apolar groups. The desired 1,4-disubstituted-1,2,3-triazoles **11a–q** were isolated in good yields ranging from 57% to 91% through adequate methods A or B (Table 1). Only compounds **11g** and **11i** were isolated in poor yields. For **11m**, the 2-nitrophenylboronic acid (method B) was added to the solution in order to avoid the decarboxylation of the desired compound [20].

Table 1. Copper-catalyzed azide alkyne cycloaddition to triazolo compounds **11a–q**.

Entry	R	Product	Yield (%)
1 ^a		11a	83
2 ^a		11b	88
3 ^a		11c	85
4 ^a		11d	84
5 ^a		11e	91
6 ^a		11f	79
7 ^a		11g	48
8 ^a		11h	71
9 ^a		11i	21
10 ^a		11j	78
11 ^a		11k	94
12 ^a		11l	69
13 ^b		11m	57
14 ^a		11n	63
15 ^a		11o	64
16 ^a		11p	82
17 ^a		11q	91

^a Method A: CuSO₄·5H₂O, sodium ascorbate, *t*BuOH/H₂O (2:1), 40 °C, time (followed by thin layer chromatography (TLC)); ^b Method B: 2-nitrophenylboronic acid, CH₂Cl₂, rt, 42 h.

From the antiviral evaluation of **11a–q** (see hereafter), it appears that compounds **11a**, **11c**, **11e**, **11j**, and **11l** have a >40% inhibition of HBV, at 10 μ M, with low cytotoxicity. Thus, we focused our attention only to the synthesis of their HDP/POC analogs **15a**, **15c**, **15e**, **15j**, **15l**, (Scheme 2). Starting from HDP/POC allylphosphonate **12**, obtained from dimethylallylphosphonate according to our previous method [14], a cross metathesis reaction of **12** and 2-methyl-2-propen-1-ol (**8**) in dry dichloromethane using the Hoveyda–Grubbs catalyst (15 mol%) under ultrasonic irradiation at 55 °C during 24 h afforded the desired compound **13** in 88% yield as only *E*-isomer.



Scheme 2. Reagents and conditions: (a) Hoveyda–Grubbs catalyst (15 mol%), dry CH₂Cl₂, 55 °C, 24 h, 88%; (b) (i) MsCl, Et₃N, dry CH₂Cl₂, 0 °C to rt, 40 min; (ii) NaN₃, DMF, rt, 5 h, 84%; (c) CuSO₄·5H₂O, sodium ascorbate, *t*BuOH/H₂O (2:1), 40 °C, 2~18 h, 68~80%.

Compound **13** was then activated by mesylation from 0 °C to room temperature (rt) in dry dichloromethane in the presence of methanesulfonyl chloride during 40 min and the corresponding sulfone was directly engaged in the next step without further purification. Mesylated intermediate was then solubilized in DMF, in the presence of sodium azide at room temperature for 5 h to afford compound **14** in 84% yield. The structure of **14** was confirmed by NOESY NMR experiment (Figure 2).





Figure 2. NOESY NMR spectra of **14**.

Finally, the CuAAC reaction of **14** with various substituted phenylacetylenes and non-aromatic terminal alkynes afforded a series of HDP/POC-(1,4-disubstituted-1,2,3-triazol)-2'-methyl-but-2'-enylphosphonate **15a**, **15c**, **15e**, **15j**, **15l**, respectively, in good yields ranging from 68% to 80%.


2.2. Antiviral Evaluation

All synthesized compounds, the (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleosides phosphonate prodrugs **11a–q**, **15a**, **15c**, **15e**, **15j**, **15l**, were tested for their antiviral activities in vitro against HIV, HBV and SARS-CoV-2 viruses; the results are summarized in Table 2 and represent means from triplicate wells.

Table 2. Antiviral activity and cytotoxicity of synthesized compounds in cellular assays at 10 μ M.



11a-q



15a-c,e,j,l

Cmpd	HBV		SARS-CoV-2		HIV	MTS	
	% Inhibition		% Cell Viability	% Inhibition	% Inhibition	Cytotoxicity (IC ₅₀ , μ M)	
	Huh7	HepAD38	Huh7	Vero E6	PBM	PBM	HepG2
11a	51	19.6	96	<1	<1	50.2	18.3
11b	25	14.4	88	<1	<1	19.4	16.2
11c	42	<1	89	<1	44.4	47.8	51.8
11d	39	38.8	100	<1	41.8	23.7	59.6
11e	50	33.5	95	<1	29.9	9.2	90.8
11f	<1	36.3	100	<1	30.7	25.5	>100
11g	10	17.3	79	<1	12.3	28.3	>100
11h	28	15.1	100	12	<1	76.4	>100
11i	33	6.1	95	<1	28.4	75.1	>100
11j	40	31.3	100	<1	<1	76.8	>100
11k	<1	6.1	100	5	42	51.5	57.3
11l	40	42.6	100	10	38.8	23.5	85.3
11m	12	41.3	57	<1	12.9	>100	>100
11n	28	3.9	60	<1	<1	40.9	>100
11o	<1	41.2	60	<1	22.4	67.5	>100
11p	14	<1	54	<1	36.4	78.3	>100
11q	<1	<1	90	<1	31.2	80.6	>100
15a	<1	ND	95	<1	ND	ND	ND
15c	14	28.8	47	<1	28.2	50.5	>100
15e	8	ND	100	<1	ND	ND	ND
15j	62	<1	74	<1	32.2	43.1	66.4
15l	12	ND	100	<1	ND	ND	ND
Entecavir	92	-	96	-	-	-	-
Remdesivir	-	-	-	100	-	-	-

ND, not determined; PBM, peripheral blood mononuclear; cmpd, compound.

None of the compounds tested displayed anti-HIV activity compared to positive control AZT (EC₅₀ of 0.008 μ M (data not shown). None of the compounds displayed anti-SARS-CoV-2 activity compared to positive control remdesivir. Compounds **11a,c–e**, **11j** and **11l** were found to exhibit a moderate anti-HBV activity compared to entecavir (on Huh7 cells) and lamivudine (on HepAd38).

It is worth noting that the substituent on triazole ring has a dramatic effect on HBV activity. In fact, compounds with hydrophobic aryl groups (electron-donating **11a–e** and electron-withdrawing **11l**) exhibited good activity (except for **11b**), whereas triazolyl-ANPs with alkyl (**11f,g**) or polar substituents such as alcohol (**11h**), aldehyde (**11i**), formamide (**11j**) and amide (**11k**) and carboxylic derivatives (**11m–q**) have only low activity. We can speculate that the hydrophobic pocket (formed by A87, F88, P177, L180, and M2) found in the rear of the RT dNTP binding site of HBV could interact with hydrophobic aryl residues through donor atom- π interaction [21].

Compound **15j**, a HDP/POC prodrug, a ribavirin analog, is the most active drug against HBV in this serial, with 62% inhibition at 10 μM . However, generally speaking, the bis(POC) ester prodrugs are more active than their HDP/POC counterparts. The cytotoxicity of test compounds was performed in different cell systems. Positive control cycloheximide exhibited expected toxicity in the peripheral blood mononuclear (PBM) and HepG2 cells, with an IC_{50} (μM) of 1.0 and 1.5 μM , respectively (data not shown).

3. Materials and Methods

3.1. Chemistry General Section

Commercially available chemicals were provided as reagent grade and used as received. Some reactions requiring anhydrous conditions were carried out using oven-dried glassware and under an atmosphere of dry argon. All anhydrous solvents were provided from commercial sources as very dry reagents. The reactions were monitored by thin layer chromatography (TLC) analysis using silica gel precoated plates (Kieselgel 60F254, E. Merck). Compounds were visualized by UV irradiation and/or spraying with sulfuric acid (H_2SO_4 5% in ethanol) stain followed by charring at average 150 $^\circ\text{C}$. Flash column chromatography was performed on silica gel 60 M (0.040–0.063 mm, E. Merck). The infrared spectra were measured with the Perkin–Elmer Spectrometer. The ^1H and ^{13}C NMR spectra were recorded on the BrukerAvance DPX 250 or BrukerAvance 400 Spectrometer (Bruker, Champs sur Marne, France). Chemical shifts are given in ppm and are referenced to the deuterated solvent signal or to TMS as internal standard and multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Carbon multiplicities were assigned by distortionless enhancement by polarization transfer (DEPT) experiments. ^1H and ^{13}C signals were attributed on the basis of H–H and H–C correlations. High resolution mass spectra were performed on a Bruker Q-TOF MaXis spectrometer (Bruker Daltonics, Bremen, Germany) by the “Fédération de Recherche” ICOA/CBM (FR2708) platform. LC-MS data were acquired on a Thermo-Fisher UHPLC-MSQ system equipped with an electron spray ionization source (ESI). The temperature of the source was maintained at 350 $^\circ\text{C}$. Initially, the cone voltage was set at 35 V and after 5 min was increased to 75 V. In full scan mode, data were acquired between 100 and 1000 m/z in the positive mode with a 1.00 s scan time. In addition, a UV detection was performed with a diode array detector at three wavelengths 273, 254 and 290 nm, respectively. A water/methanol (70%/30%) solution mixture with 0.1% formic acid was used as the mobile phase. The composition of the mobile phase was increased to 100% methanol with 0.1% formic acid with a 7% ramp. The flow rate was set at 0.300 mL min^{-1} . Samples diluted in the mobile phase were injected (3 μL) on a C18 column (X-terra, Waters), with a 2.1 mm internal diameter, and 100 mm length, and placed into an oven at 40 $^\circ\text{C}$. The electronic extraction of ions was performed and the subsequent areas under the corresponding chromatographic peaks determined. The compounds’ name follows the IUPAC recommendations.

3.2. Antiviral Evaluation

3.2.1. HBV Assay

In Huh7 cells: antiviral activity against HBV in cell culture was measured as previously described [22]. Briefly, Huh7 cells were transfected with plasmid pCI_HBVpg1820 containing 1.1 unit of HBV genome under the control of a human cytomegalovirus (CMV) promoter. The drugs were stored at 1000 \times in DMSO at -20 $^\circ\text{C}$. For each experiment, the drugs were diluted in DMEM cell culture medium (Thermo Fisher Scientific, Artenay, France) to a final concentration of 10 μM . All drugs were tested in triplicate in two independent experiments. After 4 days of culture, intracapsid viral DNA was quantified by duplex real-time PCR, using primers described elsewhere, on a LightCycler 480 II apparatus (Roche Diagnostics France, Meylan, France) using TaqMan Universal PCR Mastermix II without UNG (Thermo Fisher Scientific, Artenay, France). Cells were quantified using primers by real-time PCR, using primers HPRT1_F (5'-TGCAGACTTTGCTTTCCTTGGTC) and HPRT1_R (5'-CAAGCTTGCGACCTTGACCATC), on a LightCycler 480 II apparatus

(Roche) using a LightCycler[®] 480 SYBR Green I Master (Roche Diagnostics France, Meylan, France). Cycling reactions were performed with the following parameters: 5 min at 95 °C, followed by 45 cycles of 10 s at 95 °C, 15 s at 60 °C, 10 s at 72 °C. The inhibition of HBV replication (%) and cell culture viability (%) were quantified using the following formulas.

$$\text{Inhibition of HBV replication (\%)} = 1 - \frac{\text{HBV DNA copy number}_{\text{Drug}}}{\text{HBV DNA copy number}_{\text{Cell culture medium}}}$$

$$\text{Cell viability (\%)} = \frac{\text{HPRT1 DNA copy number}_{\text{Drug}}}{\text{HPRT1 DNA copy number}_{\text{Cell culture medium}}}$$

In HepAD38 cells [23] were seeded at 50,000 cells/well in collagen-coated 96-well plates. Test compounds or 2',3'-didéoxy-3'-thiacytidin (3TC) (control) were added to HepAD38 cells to a final concentration of 10 µM.

Real-Time PCR for HBV DNA. The experiment lasted 7 days. On day 7, total DNA was purified from the supernatant using a commercially available kit (DNeasy 96 Blood & Tissue kit, Qiagen). The HBV DNA was amplified in a real-time PCR assay using a LightCycler 480 (Roche) as described elsewhere [24]. All samples were tested in duplicate in two to three independent experiments. Analysis: The concentration of compound that inhibited HBV DNA replication by 50% (EC₅₀) was determined by linear regression.

3.2.2. HIV Assay

The assay was performed as described by Schinazi et al. [25,26] with minor modifications [26]. Briefly, human PBM cells were stimulated with PHA/IL-2 prior to infection with HIV-1 LAI (MOI 0.1) for 5 days in the presence of test compounds with a final concentration of 10 µM (LA-338-366) or AZT (control). The supernatants were harvested, and the HIV-1 RT was quantified. The median effective concentrations (EC_{50/90}) were determined using the method of Belen'kii and Schinazi [27].

3.2.3. SARS-CoV-2 Assay

Vero E6 (ATCC CRL-1586) cells were grown in a minimal essential medium (MEM) (Life Technologies, Carlsbad, CA, USA) with 7.5% heat-inactivated fetal calf serum (FCS), at 37 °C with 5% CO₂ with 1% penicillin/streptomycin (PS, 5000 U.mL⁻¹ and 5000 µg.mL⁻¹, respectively; Life Technologies) and supplemented with 1% non-essential amino acids (Life Technologies). SARS-CoV-2 strain BavPat1 was obtained from Pr Drosten through EVA GLOBAL (<https://www.european-virus-archive.com>, accessed on 23 February 2021). To prepare the virus working stock, a 25 cm² culture flask of confluent Vero E6 cells growing with MEM medium with 2.5% FBS (Life Technologies) was inoculated at MOI 0.001. The cell supernatant medium was harvested at the peak of infection and supplemented with 25 mM HEPES (Sigma, St. Louis, MO, USA) before being stored frozen in small aliquots at −80 °C. All experiments were conducted in a BSL3 laboratory. One day prior to infection, for the antiviral screening 5 × 10⁴ Vero E6 cells were seeded in 100 of µL the assay medium (containing 2.5% FCS) in 96 well plates. The next day, four 2-fold serial dilutions of compounds (20 µM to 2.5 µM, in duplicate) were added to the cells (25 µL/well, in the assay medium) as well as two internal well controls of viral inhibition corresponding to the addition of 10 µM of Remdesivir (BLDpharm, Hyderabad, India). Three virus control wells were supplemented with 25 µL of assay medium (positive controls hereafter named vc) and three cell control wells were supplemented with 50 µL of the medium (negative controls, hereafter named nc). After 15 min, 25 µL of a virus mix diluted in 2.5% FCS-containing medium was added to the wells at MOI 0.002. Three days after infection, the cell supernatant media was discarded and CellTiter-Blue[®] reagent (Promega, Madison, WI, USA) was added following the manufacturer's instructions. Plates were incubated for 2 h prior to recording the fluorescence (560/590 nm) with a Tecan Infinite 200Pro machine. From the measured OD_{590nm}, the inhibition percentage was calculated as follows: ((OD_{590nm} value- mean OD_{590nm} value of vc)/(mean OD_{590nm} of nc- mean

OD_{590nm} value of vc)*100. All data obtained were analyzed using GraphPad Prism 7 software (Graph pad software).

3.2.4. Cytotoxicity Assays

Assays were performed in human peripheral blood mononuclear (PBM) and human liver (HepG2) cells via MTS assay using the CellTiter 96[®] Non-Radioactive Cell Proliferation (Promega) kit as previously described³. Cytotoxicity was expressed as the concentration of test compounds that inhibited cell proliferation by 50% (IC₅₀) and calculated using the Chou and Talalay method [28].

3.3. Experimental Section

(E)-4-Hydroxy-3-methyl-but-2-enyl-bis(POC)phosphonate (9)

To a solution of *bis*(POC) allylphosphonate (7) (500 mg, 2.0 eq., 1.41 mmol) and 2-methyl-2-propen-1-ol (8) (59 μ L, 1.0 eq., 0.71 mmol) in dry CH₂Cl₂ (5 mL), Hoveyda–Grubbs catalyst (66 mg, 15 mol%, 0.11 mmol) was added. The catalyst addition was performed in five equal portions of 3 mol% (13.20 mg, 0.021 mmol) at t = 0, 3, 6, 9 and 21 h over the course of the reaction. The solution was sonicated at 55 °C under nitrogen atmosphere for 24 h. Volatiles were evaporated and the residue was purified by silica gel column chromatography (EtOAc/PE, 7:3) to give the desired phosphonate derivative 9 (264 mg, 94%) as brown oil. ¹H NMR (400 MHz, CDCl₃) δ 5.65–5.57 (m, 4H, O-CH₂-O), 5.41–5.37 (m, 1H, CH=C), 4.87 (sept., J = 6.2 Hz, 2H, CH(CH₃)₂), 3.98 (d, J = 5.3 Hz, 2H, CH₂-OH), 2.69 (dd, J = 22.7, 7.6 Hz, 2H, CH₂-P), 2.34 (s, 1H, OH), 1.65 (d, J = 4.5 Hz, 3H, CH₃), 1.28 (d, J = 6.3 Hz, 12H, CH(CH₃)₂). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 141.6, 141.5 (CH=C), 111.6, 111.5 (CH=C), 84.1, 84.1 (O-CH₂-O), 73.3 (CH(CH₃)₂), 68.0, 68.0 (CH₂-OH), 27.3, 25.9 (CH₂-P), 21.6 (CH(CH₃)₂), 13.9, 13.9 (CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 28.80. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₅H₂₈O₁₀P: 399.14146, found: 399.14151.

(E)-4-Azido-3-methyl-but-2-enyl-bis(POC)phosphonate (10)

To a solution of (E)-4-hydroxy-3-methyl-but-2-enyl-*bis*(POC)phosphonate 9 (264 mg, 1.0 equiv., 0.66 mmol) in anhydrous CH₂Cl₂ (5 mL) were added dropwise methanesulfonyl chloride (56 μ L, 1.1 equiv., 0.73 mmol) and anhydrous triethylamine (102 μ L, 1.1 equiv., 0.73 mmol) at 0 °C under the argon. After 30 min stirring at room temperature, the mixture was diluted with CH₂Cl₂ and washed with brine solution (3 \times 10 mL). The organic layers were dried over MgSO₄, filtrated and concentrated in vacuo. The residue was directly used for the next step without further purification. Thus, it was dissolved in anhydrous DMF (8 mL) and sodium azide (216 mg, 5.0 equiv., 3.32 mmol) was added under nitrogen atmosphere. After 5 h stirring at room temperature, the mixture was diluted with EtOAc, washed with water and then extracted with EtOAc. The combined organic layers were washed with brine solution (5 \times 10 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/PE, 4:6) to give 10 (261 mg, 93%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 5.71–5.61 (m, 4H, O-CH₂-O), 5.48–5.42 (m, 1H, CH=C), 4.92 (sept., J = 6.2 Hz, 2H, CH(CH₃)₂), 3.71 (d, J = 4.0 Hz, 2H, CH₂-N₃), 2.75 (dd, J = 23.1, 7.9, Hz, 2H, CH₂-P), 1.73 (d, J = 4.5 Hz, 3H, CH₃), 1.32 (d, J = 6.2 Hz, 12H, CH(CH₃)₂). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 136.2, 136.1 (C=CH), 116.4, 116.3 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.3 (CH(CH₃)₂), 58.6, 58.6 (CH₂-N₃), 27.6 (CH₂-P), 26.2 (CH₂-P), 21.6 (CH(CH₃)₂), 14.9, 14.9 (CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.85. IR ν_{\max} 2985.61, 2937.37, 2100.12, 1755.01, 1255.06, 1031.52, 984.34, 949.97, 904.26, 832.67, 788.47 cm⁻¹. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₁₅H₂₆N₃NaO₉P: 446.12988, found: 446.12990.

General procedures A for CuAAC reaction

To a solution of (E)-4-Azido-3-methyl-but-2-enyl-*bis*(POC)phosphonate 10 (1.0 equiv.) and alkyne (1.3 equiv.) in *t*BuOH/H₂O (2:1) were added sodium ascorbate (0.6 equiv.) and CuSO₄·5H₂O (0.1 equiv.). The resulting suspension was stirred at 40 °C until completion (followed by TLC), then the crude mixture was co-evaporated five times with methanol

(10 mL). The residue was purified by silica gel column chromatography using elution gradient of petroleum ether/ethyl acetate to give the desired *bis*(POC) phosphonate derivatives.

[[*E*]-4-[4-(4-Propylphenyl)triazol-1-yl]-3-methyl-but-2-enyl]-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate (**11a**)

The title compound was prepared from **10** (101 mg, 0.24 mmol) and 1-ethynyl-4-propylbenzene (49 μ L mg, 0.31 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4:6), the desired pure compound **11a** (112 mg, 83%) was obtained as a colorless oil. ¹H NMR (250 MHz, CDCl₃) δ 7.76 (s, 1H, H⁵), 7.74 (d, *J* = 5.7 Hz, 2H, H^{Ar}), 7.25–7.17 (d, *J* = 8.5 Hz, 2H, H^{Ar}), 5.77–5.51 (m, 4H, O-CH₂-O; 1H, CH=C), 4.98–4.80 (m, 2H, CH₂-N; 2H, CH(CH₃)₂), 2.78 (dd, *J* = 23.1, 7.8 Hz, 2H, CH₂-P), 2.59 (t, *J* = 7.6 Hz, 2H, Ar-CH₂), 1.70–1.58 (m, 3H, CH₃; 2H, Ar-CH₂-CH₂), 1.27 (d, *J* = 6.3 Hz, 12H, CH(CH₃)₂), 0.93 (t, *J* = 7.3 Hz, 3H, Ar-CH₂-CH₂-CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 148.3 (C^{q,Ar}), 142.7 (C^{q,Ar}), 135.9, 135.7 (CH=C), 128.9 (CH^{Ar}), 128.1 (C^{q,Ar}), 125.6 (CH^{Ar}), 119.0 (CH^{Ar}), 118.1, 118.0 (CH=C), 84.1, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.8, 57.8 (CH₂-N), 37.8 (Ar-CH₂), 27.8, 26.4 (CH₂-P), 24.5 (Ar-CH₂-CH₂), 21.6, 21.6 (CH(CH₃)₂), 14.2, 14.2 (CH₃), 13.8 (Ar-CH₂-CH₂-CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.47. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₂₆H₃₉N₃O₉P: 568.24184, found: 568.24217.

[[*E*]-4-[4-(4-Butylphenyl)triazol-1-yl]-3-methyl-but-2-enyl]-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate (**11b**)

The title compound was prepared from **10** (102 mg, 0.24 mmol) and 1-butyl-4-ethynylbenzene (55 μ L, 0.31 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4:6), the desired pure compound **11b** (123 mg, 88%) was obtained as a colorless oil. ¹H NMR (250 MHz, CDCl₃) δ 7.76 (d, *J* = 7.8 Hz, 2H, H^{Ar}), 7.75 (s, 1H, H⁵), 7.22 (d, *J* = 7.8 Hz, 2H, H^{Ar}), 5.73–5.63 (m, 4H, O-CH₂-O), 5.60–5.54 (m, 1H, CH=C), 4.94 (d, *J* = 5.0 Hz, 2H, CH₂-N), 4.90 (sept., *J* = 6.3 Hz, 2H, CH(CH₃)₂), 2.80 (dd, *J* = 23.3, 7.9 Hz, 2H, CH₂-P), 2.62 (t, *J* = 7.8 Hz, 2H, Ar-CH₂-CH₂-CH₂-CH₃), 1.64–1.58 (m, 3H, CH₃; 2H, Ar-CH₂-CH₂-CH₂-CH₃), 1.40–1.34 (m, 2H, Ar-CH₂-CH₂-CH₂-CH₃), 1.28 (d, *J* = 6.3 Hz, 12H, CH(CH₃)₂), 0.92 (t, *J* = 7.3 Hz, 3H, Ar-CH₂-CH₂-CH₂-CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 148.4 (C^{q,Ar}), 143.0 (C^{q,Ar}), 135.9, 135.8 (CH=C), 128.8 (CH^{Ar}), 128.0 (C^{q,Ar}), 125.7 (CH^{Ar}), 119.0 (CH^{Ar}), 118.1, 118.0 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.8, 57.8 (CH₂-N), 35.4 (Ar-CH₂-CH₂-CH₂-CH₃), 33.5 (Ar-CH₂-CH₂-CH₂-CH₃), 27.8 (CH₂-P), 26.4 (CH₂-P), 22.3 (Ar-CH₂-CH₂-CH₂-CH₃), 21.6, 21.6 (CH(CH₃)₂), 14.2, 14.2 (CH₃), 13.9 (Ar-CH₂-CH₂-CH₂-CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.46. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₂₇H₄₀N₃NaO₉P: 604.23943, found: 604.23935.

[[*E*]-4-[4-(4-Pentylphenyl)triazol-1-yl]-3-methyl-but-2-enyl]-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate (**11c**)

The title compound was prepared from **10** (96 mg, 0.23 mmol) and 1-ethynyl-4-pentylbenzene (57 μ L, 0.29 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4:6), the desired pure compound **11c** (115 mg, 85%) was obtained as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (s, 2H, H^{Ar}), 7.74 (s, 1H, H⁵), 7.22 (d, *J* = 7.8 Hz, 2H, H^{Ar}), 5.72–5.64 (m, 4H, O-CH₂-O), 5.61–5.56 (m, 1H, CH=C), 4.94 (d, *J* = 5.1 Hz, 2H, CH₂-N), 4.90 (sept., *J* = 6.2 Hz, 2H, CH(CH₃)₂), 2.80 (dd, *J* = 23.1, 7.8 Hz, 2H, CH₂-P), 2.62 (t, *J* = 7.8 Hz, 2H, Ar-CH₂-(CH₂)₃-CH₃), 1.64–1.59 (m, 3H, CH₃; 2H, Ar-CH₂-CH₂-CH₂-CH₂-CH₃), 1.33–1.32 (m, 4H, Ar-CH₂-CH₂-CH₂-CH₂-CH₃), 1.28 (d, *J* = 6.3 Hz, 12H, CH(CH₃)₂), 0.89 (t, *J* = 7.3 Hz, 3H, Ar-(CH₂)₄-CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 148.4 (C^{q,Ar}), 143.0 (C^{q,Ar}), 135.9, 135.7 (CH=C), 128.8 (CH^{Ar}), 128.0 (C^{q,Ar}), 125.7 (CH^{Ar}), 119.0 (CH^{Ar}), 118.1, 118.0 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.8, 57.8 (CH₂-N), 35.7 (Ar-CH₂-(CH₂)₃-CH₃), 31.4, 31.1 (Ar-CH₂-CH₂-CH₂-CH₂-CH₃), 27.8 (CH₂-P), 26.4 (CH₂-P), 23.9 (Ar-CH₂-CH₂-CH₂-CH₂-CH₃), 22.5 (Ar-(CH₂)₃CH₂-CH₃), 21.6, 21.6 (CH(CH₃)₂), 14.2, 14.2 (CH₃), 14.0 (Ar-(CH₂)₄-CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.51. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₂₈H₄₂N₃NaO₉P: 618.25508, found: 618.25473.

[[*(E)*-4-[4-(4-Hexylphenyl)triazol-1-yl]-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11d**)

The title compound was prepared from **10** (93 mg, 0.22 mmol) and 1-ethynyl-4-hexylbenzene (60 μ L mg, 0.29 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 35:65), the desired pure compound **11d** (112 mg, 84%) was obtained as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, *J* = 5.4 Hz, 2H, H^{Ar}), 7.72 (s, 1H, H⁵), 7.20 (d, *J* = 7.8 Hz, 2H, H^{Ar}), 5.70–5.62 (m, 4H, O-CH₂-O), 5.59–5.53 (m, 1H, CH=C), 4.92 (d, *J* = 3.8 Hz, 2H, CH₂-N), 4.88 (sept., *J* = 6.2 Hz, 2H, CH(CH₃)₂), 2.78 (dd, *J* = 23.1, 7.8 Hz, 2H, CH₂-P), 2.60 (t, *J* = 7.8 Hz, 2H, Ar-CH₂-(CH₂)₄-CH₃), 1.62–1.56 (m, 3H, CH₃; 2H, Ar-CH₂-CH₂-(CH₂)₃CH₃), 1.33–1.25 (m, 18H, Ar-CH₂-CH₂-(CH₂)₃CH₃, CH(CH₃)₂), 0.86 (t, *J* = 7.0 Hz, 3H, Ar-(CH₂)₅-CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 148.3 (C^{q,Ar}), 143.0 (C^{q,Ar}), 135.9, 135.8 (CH=C), 128.8 (CH_{Ar}), 128.0 (C^{q,Ar}), 125.7 (CH^{Ar}), 119.1 (CH^{Ar}), 118.1, 117.9 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.8, 57.7 (CH₂-N), 35.7 (Ar-CH₂-(CH₂)₄-CH₃), 31.7, 31.3 (Ar-CH₂-CH₂-(CH₂)₃CH₃), 28.9 (Ar-CH₂-CH₂-CH₂-CH₂-CH₂-CH₃), 27.8 (CH₂-P), 26.4 (CH₂-P), 23.9 (Ar-CH₂-CH₂-CH₂-CH₂-CH₂-CH₃), 22.6 (Ar-(CH₂)₄CH₂-CH₃), 21.6, 21.6 (CH(CH₃)₂), 14.2, 14.21 (CH₃), 14.1 (Ar-(CH₂)₅-CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.50. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₂₉H₄₄N₃NaO₉P: 632.27073, found: 632.27074.

[[*(E)*-4-[4-(4-Heptylphenyl)triazol-1-yl]-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11e**)

The title compound was prepared from **10** (113 mg, 0.27 mmol) and 1-ethynyl-4-heptylbenzene (78 μ L, 0.35 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 3:7), the desired pure compound **11e** (151 mg, 91%) was obtained as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 2.4 Hz, 2H, H^{Ar}), 7.74 (s, 1H, H⁵), 7.22 (d, *J* = 7.8 Hz, 2H, H^{Ar}), 5.72–5.64 (m, 4H, O-CH₂-O), 5.62–5.56 (m, 1H, CH=C), 4.94 (d, *J* = 3.8 Hz, 2H, CH₂-N), 4.89 (sept., *J* = 6.3 Hz, 2H, CH(CH₃)₂), 2.79 (dd, *J* = 23.1, 7.8 Hz, 2H, CH₂-P), 2.61 (t, *J* = 7.8 Hz, 2H, Ar-CH₂-(CH₂)₅-CH₃), 1.64–1.58 (m, 3H, CH₃; 2H, Ar-CH₂-CH₂-(CH₂)₄CH₃), 1.33–1.25 (m, 20H, Ar-CH₂-CH₂-(CH₂)₄CH₃, CH(CH₃)₂), 0.87 (t, *J* = 7.1 Hz, 3H, Ar-(CH₂)₆-CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 148.4 (C^{q,Ar}), 143.0 (C^{q,Ar}), 135.9, 135.8 (CH=C), 128.8 (CH_{Ar}), 128.0 (C^{q,Ar}), 125.6 (CH^{Ar}), 119.0 (CH^{Ar}), 118.2, 118.1 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.9, 57.8 (CH₂-N), 35.7 (Ar-CH₂-(CH₂)₅-CH₃), 31.8, 31.4 (Ar-CH₂-CH₂-(CH₂)₄CH₃), 29.7, 29.2, 29.1 (Ar-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-CH₃), 27.8 (CH₂-P), 26.4 (CH₂-P), 22.6 (Ar-(CH₂)₅CH₂-CH₃), 21.6, 21.5 (CH(CH₃)₂), 14.2, 14.1 (CH₃), 14.1 (Ar-(CH₂)₆-CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.46. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₃₀H₄₇N₃O₉P: 624.30444, found: 624.30373.

[[*(E)*-4-(4-Cyclopropyltriazol-1-yl)-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11f**)

The title compound was prepared from **10** (94 μ L, 0.22 mmol) and cyclopropylacetylene (24 μ L, 0.29 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4:6), the desired pure compound **11f** (86 mg, 79%) was obtained as a colorless oil. ¹H NMR (250 MHz, CDCl₃) δ 7.23 (s, 1H, H⁵), 5.72–5.62 (m, 4H, O-CH₂-O), 5.54–5.45 (m, 1H, CH=C), 4.92 (sept., *J* = 6.2 Hz, 2H, CH(CH₃)₂), 4.83 (d, *J* = 4.1 Hz, 2H, CH₂-N), 2.76 (dd, *J* = 23.1, 7.8 Hz, 2H, CH₂-P), 2.00–1.89 (m, 1H, CH₂CHCH₂), 1.59 (d, *J* = 5.5 Hz, 3H, CH₃), 1.31 (dd, *J* = 6.3, 1.3 Hz, 12H, CH(CH₃)₂), 0.95–0.82 (m, 4H, CH₂CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 150.7 (C^{q,Ar}), 136.01, 135.9 (CH=C), 119.4 (CH^{Ar}), 117.8, 117.7 (CH=C), 84.1, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.6, 57.6 (CH₂-N), 27.7, 26.4 (CH₂-P), 21.7, 21.6 (CH(CH₃)₂), 14.2, 14.1 (CH₃), 7.8 (CH₂CH₂), 6.7 (CH₂CHCH₂). ³¹P NMR (162 MHz, CDCl₃) δ 27.6. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₂₀H₃₃N₃O₉P: 490.19489, found: 490.19492.

[[*(E)*-4-(4-tert-Butyltriazol-1-yl)-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11g**)

The title compound was prepared from **10** (98 mg, 0.23 mmol) and 3,3-dimethyl-1-butyne (37 μ L, 0.30 mmol) following the general procedure A; the resulting suspension was stirred for 24 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 6:4), the desired pure compound **11g** (56 mg, 48%) was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.25 (s, 1H, H^5), 5.71–5.62 (m, 4H, O- CH_2 -O), 5.51–5.45 (m, 1H, CH=C), 4.92 (sept., $J = 6.2$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 4.85 (d, $J = 3.9$ Hz, 2H, CH_2 -N), 2.76 (dd, $J = 23.1, 7.8$ Hz, 2H, CH_2 -P), 1.60 (d, $J = 4.5$ Hz, 3H, CH_3), 1.33 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.31 (d, $J = 6.3$, Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CDCl_3) δ 158.2 ($\text{C}^{\text{q,Ar}}$), 153.1 (C=O), 136.1, 136.0 (CH=C), 118.4 (CH^{Ar}), 117.6, 117.5 (CH=C), 84.2, 84.1 (O- CH_2 -O), 73.4 ($\text{CH}(\text{CH}_3)_2$), 57.6, 57.5 (CH_2 -N), 30.8 ($\text{C}(\text{CH}_3)_3$), 30.3 ($\text{C}(\text{CH}_3)_3$), 27.7, 26.3 (CH_2 -P), 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3, 14.2 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 27.62. HRMS (ESI): m/z [$\text{M}+\text{H}$] $^+$ calcd for $\text{C}_{21}\text{H}_{37}\text{N}_3\text{O}_9\text{P}$: 506.22619, found: 506.22601.

[[*(E)*-4-[4-(Hydroxymethyl)triazol-1-yl]-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11h**)

The title compound was prepared from **10** (105 mg, 0.25 mmol) and propargyl alcohol (19 μ L, 0.32 mmol) following the general procedure A; the resulting suspension was stirred for 24 h at 40 °C. After purification on a silica gel column chromatography (MeOH/ CH_2Cl_2 , 5/95), the desired pure compound **11h** (84 mg, 71%) was obtained as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.55 (s, 1H, H^5), 5.67–5.59 (m, 4H, O- CH_2 -O), 5.49–5.44 (m, 1H, CH=C), 4.92–4.86 (m, 4H, $\text{CH}(\text{CH}_3)_2$), CH_2 -N), 4.75 (s, 2H, CH_2OH), 2.74 (dd, $J = 23.1, 7.8$ Hz, 2H, CH_2 -P), 1.57 (d, $J = 4.6$ Hz, 3H, CH_3), 1.28 (d, $J = 5.6$, Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CDCl_3) δ 153.2 (C=O), 135.7, 135.6 (CH=C), 121.5 (CH^{Ar}), 118.1, 118.0 (CH=C), 84.1, 84.0 (O- CH_2 -O), 73.5 ($\text{CH}(\text{CH}_3)_2$), 57.7, 57.6 (CH_2 -N), 56.5 (CH_2OH), 27.7, 26.3 (CH_2 -P), 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3, 14.2 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 27.40. HRMS (ESI): m/z [$\text{M}+\text{Na}$] $^+$ calcd for $\text{C}_{18}\text{H}_{30}\text{N}_3\text{NaO}_{10}\text{P}$: 502.156102, found: 502.155885.

[[*(E)*-4-(4-Formyltriazol-1-yl)-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11i**)

The title compound was prepared from **10** (82 mg, 0.19 mmol) and 3,3-diethoxy-1-propyne (36 μ L, 0.25 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 6/4), the desired pure compound **11i** (19 mg, 21%) was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 10.14 (s, 1H, CHO), 8.14 (s, 1H, H^5), 5.71–5.63 (m, 4H, O- CH_2 -O), 5.60–5.57 (m, 1H, CH=C), 4.98 (d, $J = 3.9$ Hz, 2H, CH_2 -N), 4.92 (sept., $J = 6.2$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 2.78 (dd, $J = 23.3, 7.8$ Hz, 2H, CH_2 -P), 1.63 (d, $J = 4.8$ Hz, 3H, CH_3), 1.31 (d, $J = 6.2$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CDCl_3) δ 184.9 (CHO), 153.1 (C=O), 148.0 ($\text{C}^{\text{q,Ar}}$), 134.8, 134.6 (CH=C), 125.2 (CH^{Ar}), 119.5, 119.4 (CH=C), 84.2, 84.1 (O- CH_2 -O), 73.5 ($\text{CH}(\text{CH}_3)_2$), 58.1, 58.0 (CH_2 -N), 27.8, 26.4 (CH_2 -P), 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3, 14.2 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 27.04. HRMS (ESI): m/z [$\text{M}+\text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{29}\text{N}_3\text{O}_{10}\text{P}$: 478.158507, found: 478.158468.

[[*(E)*-4-(4-Carbamoyltriazol-1-yl)-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11j**)

The title compound was prepared from **10** (106 mg, 0.25 mmol) and propiolamide (22 mg, 0.33 mmol) following the general procedure A; the resulting suspension was stirred for 14 h at 40 °C. After purification on a silica gel column chromatography (MeOH/ CH_2Cl_2 , 3/97), the desired pure compound **11j** (96 mg, 78%) was obtained as a colorless oil. ^1H NMR (400 MHz, Acetone- d_6) δ 8.31 (s, 1H, H^5), 7.38 (s, 1H, NH), 6.78 (s, 1H, NH), 5.70–5.63 (m, 4H, O- CH_2 -O), 5.59–5.57 (m, 1H, CH=C), 5.08 (d, $J = 4.0$ Hz, 2H, CH_2 -N), 4.91 (sept., $J = 6.2$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 2.84 (dd, $J = 22.4, 7.9$ Hz, 2H, CH_2 -P), 1.66 (d, $J = 3.9$ Hz, 3H, CH_3), 1.29 (d, $J = 6.3$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, Acetone- d_6) δ 161.6 ($\text{NH}_2\text{C}=\text{O}$), 153.1 (C=O), 143.4 ($\text{C}^{\text{q,Ar}}$), 135.4, 135.3 (CH=C), 126.0 (CH^{Ar}), 118.4, 118.3 (CH=C), 84.2, 84.1 (O- CH_2 -O), 72.8 ($\text{CH}(\text{CH}_3)_2$), 57.2, 57.1 (CH_2 -N), 27.3, 25.9 (CH_2 -P), 20.9 ($\text{CH}(\text{CH}_3)_2$), 13.6, 13.5 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 27.05. HRMS (ESI): m/z [$\text{M}+\text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{30}\text{N}_4\text{O}_{10}\text{P}$: 493.169406, found: 493.169337.

[[*(E)*-4-(4-Octanoylaminoethyl)triazol-1-yl]-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate (**11k**)

The title compound was prepared from **10** (109 mg, 0.26 mmol) and *N-N*(prop-2-yn-1-yl)octanamide (56 mg, 0.33 mmol) following the general procedure A; the resulting suspension was stirred for 24 h at 40 °C. After purification on a silica gel column chromatography (MeOH/CH₂Cl₂, 3/97), the desired pure compound **11k** (147 mg, 94%) was obtained as a yellowish oil. ¹H NMR (400 MHz, CDCl₃) δ 7.51 (s, 1H, H⁵), 6.20 (s, 1H, NH), 5.70–5.62 (m, 4H, O-CH₂-O), 5.52–5.47 (m, 1H, CH=C), 4.92 (sept., *J* = 6.3 Hz, 2H, CH(CH₃)₂), 4.87 (d, *J* = 4.0 Hz, 2H, CH₂-N), 4.50 (d, *J* = 5.5 Hz, 2H, ArCH₂NH), 2.76 (dd, *J* = 23.3, 7.9 Hz, 2H, CH₂-P), 2.18 (t, *J* = 7.7 Hz, 2H, O=CCH₂(CH₂)₅CH₃), 1.65–1.59 (m, 5H, CH₃; O=CCH₂CH₂(CH₂)₄CH₃), 1.31 (d, *J* = 6.4 Hz, 12H, CH(CH₃)₂), 1.24–1.28 (m, 8H, O=CCH₂CH₂(CH₂)₄CH₃), 0.86 (t, *J* = 6.9 Hz, 3H, O=C(CH₂)₆CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 173.2 (NHC=O), 153.2 (C=O), 145.1 (C^{q,Ar}), 135.6, 135.5 (CH=C), 121.8 (CH^{Ar}), 118.2, 118.1 (CH=C), 84.6, 84.1 (O-CH₂-O), 73.4 (CH(CH₃)₂), 57.8, 57.7 (CH₂-N), 36.6 (ArCH₂NH), 35.0 (O=CCH₂(CH₂)₅CH₃), 31.7 (O=CCH₂CH₂(CH₂)₄CH₃), 29.3 (O=CCH₂CH₂CH₂(CH₂)₃CH₃), 29.0 (O=C(CH₂)₃CH₂CH₂CH₂CH₃), 27.8 (CH₂-P), 26.4 (CH₂-P), 25.6 (O=C(CH₂)₄CH₂CH₂CH₃), 22.6 (O=C(CH₂)₅CH₂CH₃), 21.6, 21.6 (CH(CH₃)₂), 14.3, 14.2 (CH₃), 14.1 (O=C(CH₂)₆CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.31. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₂₆H₄₅N₄NaO₁₀P: 627.276551, found: 627.275980.

[[*(E)*-4-(4-Nitrophenyl)triazol-1-yl]-3-methyl-but-2-enyl]-isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate (**11l**)

The title compound was prepared from **10** (100 mg, 0.24 mmol) and 1-ethynyl-4-nitrobenzene (45 mg, 0.31 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 5/5), the desired pure compound **11l** (93 mg, 69%) was obtained as a yellowish oil. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 8.5 Hz, 2H, H^{Ar}), 8.04 (d, *J* = 8.5 Hz, 2H, H^{Ar}), 8.00 (s, 1H, H⁵), 5.73–5.60 (m, 5H, O-CH₂-O, CH=C), 4.98 (d, *J* = 3.7 Hz, 2H, CH₂-N), 4.89 (sept., *J* = 6.4 Hz, 2H, CH(CH₃)₂), 2.81 (dd, *J* = 23.2, 7.9 Hz, 2H, CH₂-P), 1.66 (d, *J* = 4.9 Hz, 3H, CH₃), 1.28 (d, *J* = 6.2 Hz, 12H, CH(CH₃)₂). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 147.3 (C^{q,Ar}), 146.1 (C^{q,Ar}), 137.0 (C^{q,Ar}), 135.3, 135.2 (CH=C), 126.2 (CH^{Ar}), 124.2 (CH^{Ar}), 121.0 (CH^{Ar}), 119.1, 119.0 (CH=C), 84.2, 84.1 (O-CH₂-O), 73.5 (CH(CH₃)₂), 58.2, 58.1 (CH₂-N), 27.8, (CH₂-P), 26.4 (CH₂-P), 21.6, 21.5 (CH(CH₃)₂), 14.3, 14.3 (CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.26. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₂₃H₃₂N₄O₁₁P: 571.179971, found: 571.179797.

1-[(*E*)-4-[Bis(isopropoxycarbonyloxymethoxy)phosphoryl]-2-methyl-but-2-enyl]triazole-4-carboxylic acid (**11m**)

To a solution of propiolic acid (49 μL, 1.1 equiv., 0.80 mmol) and (*E*)-4-Azido-3-methyl-but-2-enyl-*bis*(POC)phosphonate **10** (307 mg, 1.0 equiv., 0.73 mmol) in anhydrous CH₂Cl₂ (10 mL) was added 2-nitrophenylboronic acid (25 mg, 0.21 equiv., 0.15 mmol) at room temperature. The solution was stirred for 42 h at room temperature. After evaporation of the solvent, the residue was purified by silica gel chromatography (MeOH/EtOAc, 1/9) to give compound **11m** (203 mg, 57%) as a colorless oil. ¹H NMR (400 MHz, CD₃OD) δ 8.28 (s, 1H, H⁵), 5.72–5.64 (m, 4H, O-CH₂-O), 5.57–5.51 (m, 1H, CH=C), 5.06 (d, *J* = 4.4 Hz, 2H, CH₂-N), 4.94 (sept., *J* = 6.4 Hz, 2H, CH(CH₃)₂), 2.91 (dd, *J* = 23.2, 7.9 Hz, 2H, CH₂-P), 1.67 (d, *J* = 4.8 Hz, 3H, CH₃), 1.33 (d, *J* = 6.2 Hz, 12H, CH(CH₃)₂). ¹³C NMR (101 MHz, CD₃OD) δ 153.2 (C=O), 136.0, 135.8 (CH=C), 126.7 (CH^{Ar}), 117.5, 117.3 (CH=C), 84.4, 84.3 (O-CH₂-O), 73.1 (CH(CH₃)₂), 57.2, 57.1 (CH₂-N), 26.8, 25.4 (CH₂-P), 20.5 (CH(CH₃)₂), 13.6, 13.1 (CH₃). ³¹P NMR (162 MHz, CD₃OD) δ 27.94. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₈H₂₉N₃O₁₁P: 494.153422, found: 494.153404.

Methyl-1-[(*E*)-4-[bis(isopropoxycarbonyloxymethoxy)phosphoryl]-2-methyl-but-2-enyl]triazole-4-carboxylate (**11n**)

The title compound was prepared from **10** (124 mg, 0.29 mmol) and methyl propiolate (34 μL, 0.38 mmol) using the general procedure A; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE,

6/4), the desired pure compound **11n** (92 mg, 63%) was obtained as a colorless oil. ^1H NMR (250 MHz, CD_3OD) δ 8.57 (s, 1H, H^5), 5.79–5.69 (m, 4H, O- CH_2 -O), 5.65–5.56 (m, 1H, CH=C), 5.14 (d, $J = 4.2$ Hz, 2H, CH_2 -N), 4.99 (sept., $J = 6.4$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 4.00 (s, 3H, OCH_3), 2.97 (dd, $J = 23.2, 7.9$ Hz, 2H, CH_2 -P), 1.74 (d, $J = 4.7$ Hz, 3H, CH_3), 1.39 (d, $J = 6.2$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CDCl_3) δ 161.0 (O=C-OMe), 153.1 (C=O), 140.3 ($\text{C}^{\text{q,Ar}}$), 135.1, 134.9 (CH=C), 127.4 (CH^{Ar}), 119.1, 118.9 (CH=C), 84.2, 84.1 (O- CH_2 -O), 73.4 ($\text{CH}(\text{CH}_3)_2$), 58.0, 57.9 (CH_2 -N), 52.1 (OCH_3), 27.8, 26.4 (CH_2 -P), 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3, 14.2 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 27.19. HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{30}\text{N}_3\text{NaO}_{11}\text{P}$: 530.151016, found: 530.151002.

Ethyl-1-[(*E*)-4-[bis(isopropoxycarbonyloxymethoxy)phosphoryl]-2-methyl-but-2-enyl] triazole-4-carboxylate (**11o**)

The title compound was prepared from **10** (120 mg, 0.28 mmol) and methyl propiolate (37 μL , 0.37 mmol) using the general procedure A; the resulting suspension was stirred for 2 h at 40 $^\circ\text{C}$. After purification on a silica gel column chromatography (EtOAc/PE, 5/5), the desired pure compound **11o** (94 mg, 64%) was obtained as a colorless oil. ^1H NMR (400 MHz, CD_3OD) δ 8.53 (s, 1H, H^5), 5.74–5.66 (m, 4H, O- CH_2 -O), 5.59–5.54 (m, 1H, CH=C), 5.10 (d, $J = 4.2$ Hz, 2H, CH_2 -N), 4.95 (sept., $J = 6.3$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 4.43 (q, $J = 7.1$ Hz, 2H, OCH_2CH_3), 2.93 (dd, $J = 23.2, 7.9$ Hz, 2H, CH_2 -P), 1.70 (d, $J = 4.8$ Hz, 3H, CH_3), 1.42 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3), 1.34 (d, $J = 6.7$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CD_3OD) δ 161.5 (O=C-OEt), 153.2 (C=O), 139.7 ($\text{C}^{\text{q,Ar}}$), 135.8, 135.6 (CH=C), 128.2 (CH^{Ar}), 117.9, 117.8 (CH=C), 84.3, 84.2 (O- CH_2 -O), 73.1 ($\text{CH}(\text{CH}_3)_2$), 60.8 (OCH_2CH_3), 57.2, 57.1 (CH_2 -N), 26.8, 25.4 (CH_2 -P), 20.5 ($\text{CH}(\text{CH}_3)_2$), 13.2 (OCH_2CH_3), 13.1, 13.0 (CH_3). ^{31}P NMR (162 MHz, CD_3OD) δ 27.92. HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{32}\text{N}_3\text{NaO}_{11}\text{P}$: 544.166666, found: 544.166837.

[[*E*]-4-(4-Methylcarbamoyl)triazol-1-yl]-3-methyl-but-2-enyl]-[isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11p**)

The title compound was prepared from **10** (121 mg, 0.29 mmol) and *N*-methylprop-2-ynamide (31 mg, 0.37 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 $^\circ\text{C}$. After purification on a silica gel column chromatography (MeOH/ CH_2Cl_2 , 1/99), the desired pure compound **11p** (118 mg, 82%) was obtained as a colorless oil. ^1H NMR (400 MHz, CD_3OD) δ 8.34 (s, 1H, H^5), 5.74–5.66 (m, 4H, O- CH_2 -O), 5.58–5.52 (m, 1H, CH=C), 5.09 (d, $J = 4.0$ Hz, 2H, CH_2 -N), 4.96 (sept., $J = 6.2$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 2.98 (s, 3H, NHCH_3), 2.92 (dd, $J = 23.2, 7.9$ Hz, 2H, CH_2 -P), 1.69 (d, $J = 4.6$ Hz, 3H, CH_3), 1.35 (d, $J = 6.3$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (101 MHz, CD_3OD) δ 161.7 (O=C- NHCH_3), 153.2 (C=O), 142.9 ($\text{C}^{\text{q,Ar}}$), 136.0, 135.8 (CH=C), 125.7 (CH^{Ar}), 117.5, 117.4 (CH=C), 84.4, 84.3 (O- CH_2 -O), 73.1 ($\text{CH}(\text{CH}_3)_2$), 57.1, 57.0 (CH_2 -N), 26.8, 25.4 (CH_2 -P), 24.7 (NHCH_3), 20.5 ($\text{CH}(\text{CH}_3)_2$), 13.1, 13.1 (CH_3). ^{31}P NMR (162 MHz, CD_3OD) δ 27.91. HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{31}\text{N}_4\text{NaO}_{10}\text{P}$: 529.167001, found: 529.166551.

[[*E*]-4-[4-(Ethylcarbamoyl)triazol-1-yl]-3-methyl-but-2-enyl]-[isopropoxycarbonyloxymethoxy]phosphoryl]oxymethyl isopropyl carbonate (**11q**)

The title compound was prepared from **10** (115 mg, 0.27 mmol) and *N*-ethylprop-2-ynamide (34 mg, 0.35 mmol) following the general procedure A; the resulting suspension was stirred for 2 h at 40 $^\circ\text{C}$. After purification on a silica gel column chromatography (MeOH/ CH_2Cl_2 , 1/99), the desired pure compound **11q** (128 mg, 91%) was obtained as a colorless oil. ^1H NMR (400 MHz, CD_3OD) δ 8.35 (s, 1H, H^5), 5.75–5.67 (m, 4H, O- CH_2 -O), 5.59–5.53 (m, 1H, CH=C), 5.09 (d, $J = 4.0$ Hz, 2H, CH_2 -N), 4.96 (sept., $J = 6.2$ Hz, 2H, $\text{CH}(\text{CH}_3)_2$), 3.47 (q, $J = 7.2$ Hz, 2H, NHCH_2CH_3), 2.93 (dd, $J = 23.1, 7.9$ Hz, 2H, CH_2 -P), 1.70 (d, $J = 4.7$ Hz, 3H, CH_3), 1.35 (d, $J = 6.2$ Hz, 12H, $\text{CH}(\text{CH}_3)_2$), 1.28 (t, $J = 7.2$ Hz, 3H, NHCH_2CH_3). ^{13}C NMR (101 MHz, CD_3OD) δ 160.8 (O=C-NH), 153.2 (C=O), 142.99 ($\text{C}^{\text{q,Ar}}$), 136.0, 135.8 (CH=C), 125.7 (CH^{Ar}), 117.5, 117.4 (CH=C), 84.4, 84.3 (O- CH_2 -O), 73.1 ($\text{CH}(\text{CH}_3)_2$), 57.1, 57.0 (CH_2 -N), 33.7 (NHCH_2CH_3), 26.8, 25.4 (CH_2 -P), 20.5 ($\text{CH}(\text{CH}_3)_2$), 13.6 (NHCH_2CH_3), 13.1, 13.0 (CH_3). ^{31}P NMR (162 MHz, CD_3OD) δ 27.91. HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{33}\text{N}_4\text{NaO}_{10}\text{P}$: 543.182651, found: 543.182603.

(*E*)-4-Hydroxy-3-methyl-but-2-enyl-(HDP/POC) phosphonate (**13**)

To a solution of (HDP/POC) allylphosphonate (**12**) (1.00 g, 2.0 equiv., 1.94 mmol) and 2-methyl-2-propen-1-ol (**8**) (81 μ L, 1.0 equiv., 0.97 mmol) in dry CH_2Cl_2 (10 mL), Hoveyda-Grubbs catalyst (91 mg, 15 mol%, 0.15 mmol) was added. The catalyst addition was performed in five equal portions of 3 mol% (18.20 mg, 0.029 mmol) at $t = 0, 3, 6, 9$ and 21 h over the course of the reaction. The solution was sonicated at 55 $^\circ\text{C}$ under nitrogen atmosphere for 24 h. Volatiles were evaporated and the residue was purified by silica gel column chromatography (EtOAc/PE, 5/5) to give the desired phosphonate derivative **13** (480 mg, 88 %) as brown oil. ^1H NMR (400 MHz, CDCl_3) δ 5.67–5.59 (m, 2H, O- CH_2 -O), 5.47–5.41 (m, 1H, CH=C), 4.92 (sept., $J = 6.3$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 4.21–4.08 (m, 2H, H^a), 4.02 (d, $J = 5.0$ Hz, 2H, CH_2 -OH), 3.47 (t, $J = 6.2$ Hz, 2H, H^c), 3.38 (t, $J = 6.7$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 2.67 (dd, $J = 22.5, 7.8$ Hz, 2H, CH_2 -P), 1.90 (quint., $J = 6.3$ Hz, 2H, H^b), 1.69 (dd, $J = 4.3, 1.3$ Hz, 3H, CH_3), 1.54 (quint., $J = 7.0$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O), 1.32–1.24 (m, 32H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O, $\text{CH}(\text{CH}_3)_2$), 0.87 (t, $J = 6.7$ Hz, 3H, $\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{13}C NMR (101 MHz, CDCl_3) δ 153.3 (C=O), 140.8, 140.7 (CH=C), 112.6, 112.5 (CH=C), 84.4, 84.3 (O- CH_2 -O), 73.1 ($\text{CH}(\text{CH}_3)_2$), 71.2 ($\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 68.1, 68.0 (CH_2 -OH), 66.5, 66.4 (C^c), 63.3, 63.2 (C^a), 31.9, 30.7, 30.6 (C^b), 29.7, 29.5, 29.4, 27.1 (CH_2 -P), 26.2, 25.7 (CH_2 -P), 22.7, 21.6 ($\text{CH}(\text{CH}_3)_2$), 14.1 ($\text{CH}_3(\text{CH}_2)_{15}\text{O}$), 13.9, 13.8 (CH_3). ^{31}P NMR (162 MHz, CDCl_3) δ 26.71. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{58}\text{O}_8\text{P}$: 565.386382, found: 565.385868.

(E)-4-Azido-3-methyl-but-2-enyl-(HDP/POC) phosphonate (**14**)

To a solution of (E)-4-hydroxy-3-methyl-but-2-enyl-(HDP/POC)phosphonate **13** (277 mg, 1.0 equiv., 0.49 mmol) in anhydrous CH_2Cl_2 (5 mL) were added dropwise methansulfonyl chloride (42 μ L, 1.1 equiv., 0.54 mmol) and anhydrous triethylamine (75 μ L, 1.1 equiv., 0.54 mmol) at 0 $^\circ\text{C}$ under the argon. After 40 min stirring at room temperature, the mixture was diluted with CH_2Cl_2 and washed with water (3×10 mL) and brine. The organic layer was dried over MgSO_4 , filtrated and concentrated in vacuo. The residue was directly used for the next step without further purification. To a solution of the above product in anhydrous DMF (8 mL) was added sodium azide (159 mg, 5.0 equiv., 2.45 mmol) under nitrogen atmosphere. After 5 h stirring at room temperature, the mixture was diluted with EtOAc and water and then extracted with EtOAc. The combined organic layer was washed with water (5×10 mL), brine, dried over MgSO_4 , and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/PE, 4/6) to give (E)-4-Azido-3-methyl-but-2-enyl-(HDP/POC) phosphonate **14** (242 mg, 84%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 5.69–5.58 (m, 2H, O- CH_2 -O), 5.51–5.41 (m, 1H, CH=C), 4.91 (sept., $J = 6.3$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 4.22–4.07 (m, 2H, H^a), 3.70 (d, $J = 3.9$ Hz, 2H, CH_2 - N_3), 3.46 (t, $J = 6.2$ Hz, 2H, H^c), 3.37 (t, $J = 6.7$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 2.68 (dd, $J = 22.7, 7.7$ Hz, 2H, CH_2 -P), 1.90 (quint., $J = 6.3$ Hz, 2H, H^b), 1.73 (d, $J = 4.3$ Hz, 3H, CH_3), 1.53 (quint., $J = 7.0$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O), 1.32–1.22 (m, 32H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O, $\text{CH}(\text{CH}_3)_2$), 0.86 (t, $J = 6.7$ Hz, 3H, $\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{13}C NMR (100 MHz, CDCl_3) δ 153.3 (C=O), 135.4, 135.3 (CH=C), 117.3, 117.2 (CH=C), 84.5, 84.4 (O- CH_2 -O), 73.1 ($\text{CH}(\text{CH}_3)_2$), 71.2 ($\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 66.5 (C^c), 63.5, 63.4 (C^a), 58.7, 58.6 (CH_2 - N_3), 32.0, 30.8, 30.7 (C^b), 29.6 (CH_2 -P), 26.1, 26.0 (CH_2 -P), 22.7, 21.6 ($\text{CH}(\text{CH}_3)_2$), 14.8, 14.7 ($\text{CH}=\text{CCH}_3$), 14.1 ($\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{31}P NMR (162 MHz, CDCl_3) δ 27.80. IR ν_{max} (neat, cm^{-1}): 2922.60, 2851.80, 2094.55, 1755.94, 1460.42, 1257.26, 1100.26, 1047.93, 992.52, 949.43 cm^{-1} . HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{57}\text{N}_3\text{O}_7\text{P}$: 590.392864, found: 590.393411.

General Procedure B for Huisgen 1,3-dipolar cycloaddition

To a solution of terminal alkyne (1.3 equiv.) and (E)-4-Azido-3-methyl-but-2-enyl-(HDP/POC) phosphonate **14** (1.0 equiv.) in $t\text{BuOH}/\text{H}_2\text{O}$ (2:1) were added sodium ascorbate (0.6 equiv.) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.1 equiv.). The resulting suspension was stirred at 40 $^\circ\text{C}$ until completion (followed by TLC), then the crude mixture was co-evaporated five times with methanol. The residue was purified by silica gel column chromatography using an elution gradient of petroleum ether/ethyl acetate to give the desired HDP/POC phosphonate derivatives.

[3-Hexadecyloxypropoxy-[(E)-3-methyl-4-[4-(4-propylphenyl)triazol-1-yl]but-2-enyl]phosphoryl]oxymethyl isopropyl carbonate (**15a**)

The title compound was prepared from **14** (123 mg, 0.21 mmol) and 1-ethynyl-4-propylbenzene (43 μ L mg, 0.27 mmol) following the general procedure B; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4/6), the desired pure compound **15a** (104 mg, 68%) was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.75 (s, 1H, H^5), 7.73 (s, 2H, H^{Ar}), 7.22 (d, $J = 8.0$ Hz, 2H, H^{Ar}), 5.70 - 5.56 (m, 3H, O- CH_2 -O; 1H, CH=C), 4.94 (s, 2H, CH_2 -N), 4.89 (sept., $J = 6.3$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 4.22 - 4.11 (m, 2H, H^{a}), 3.44 (t, $J = 6.1$ Hz, 2H, H^{c}), 3.35 (t, $J = 6.7$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 2.73 (dd, $J = 22.8, 7.8$ Hz, 2H, CH_2 -P), 2.60 (t, $J = 7.5$ Hz, 2H, Ar- $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.90 (quint., $J = 6.3$ Hz, 2H, H^{b}), 1.68–1.63 (m, 3H, CH_3 ; 2H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.52 (quint., $J = 7.0$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O), 1.29–1.25 (m, 32H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O, $\text{CH}(\text{CH}_3)_2$), 0.95 (t, $J = 7.3$ Hz, 3H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, $J = 7.0$ Hz, 3H, $\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{13}C NMR (101 MHz, CDCl_3) δ 153.3 (C=O), 148.3 ($\text{C}^{\text{q,Ar}}$), 142.8 ($\text{C}^{\text{q,Ar}}$), 128.9 (CH^{Ar}), 128.0 (CH=C), 125.6 (CH^{Ar}), 118.9 (CH=C), 118.8 (CH^{Ar}), 84.4 (O- CH_2 -O), 73.2 ($\text{CH}(\text{CH}_3)_2$), 71.2 ($\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 66.4 (C^{c}), 63.5 (C^{a}), 57.9 (CH_2 -N), 37.8 (Ar $\text{CH}_2\text{CH}_2\text{CH}_3$), 31.9, 30.7 (C^{b}), 29.6 (CH_2 -P), 24.5 (Ar $\text{CH}_2\text{CH}_2\text{CH}_3$), 22.7, 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3 (C=C CH_3), 14.1 ($\text{CH}_3(\text{CH}_2)_{15}\text{O}$), 13.7 (Ar $\text{CH}_2\text{CH}_2\text{CH}_3$). ^{31}P NMR (162 MHz, CDCl_3) δ 27.46. HRMS (ESI): m/z [$\text{M}+\text{H}$] $^+$ calcd for $\text{C}_{40}\text{H}_{69}\text{N}_3\text{NaO}_7\text{P}$: 734.486765, found: 734.486600.

[3-Hexadecyloxypropoxy-[(*E*)-3-methyl-4-[4-(4-pentylphenyl)triazol-1-yl]but-2-enyl]phosphoryl]oxymethyl isopropyl carbonate (**15c**)

The title compound was prepared from **14** (93 mg, 0.16 mmol) and 1-ethynyl-4-pentylbenzene (40 μ L, 0.21 mmol) following the general procedure B; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4/6), the desired pure compound **15c** (89 mg, 74%) was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 3.8$ Hz, 2H, H^{Ar}), 7.73 (s, 1H, H^5), 7.22 (d, $J = 8.0$ Hz, 2H, H^{Ar}), 5.70 - 5.56 (m, 3H, O- CH_2 -O; 1H, CH=C), 4.94 (s, 2H, CH_2 -N), 4.90 (sept., $J = 6.2$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 4.22–4.11 (m, 2H, H^{a}), 3.44 (t, $J = 6.1$ Hz, 2H, H^{c}), 3.35 (t, $J = 6.7$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 2.73 (dd, $J = 22.8, 7.8$ Hz, 2H, CH_2 -P), 2.62 (t, $J = 7.8$ Hz, 2H, Ar- $\text{CH}_2(\text{CH}_2)_3\text{CH}_3$), 1.90 (quint., $J = 6.3$ Hz, 2H, H^{b}), 1.65–1.61 (m, 5H, CH_3 , Ar- $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.52 (quint., $J = 7.0$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O), 1.29–1.25 (m, 36H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O, $\text{CH}(\text{CH}_3)_2$, Ar- $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, $J = 6.9$ Hz, 6H, Ar- $(\text{CH}_2)_4\text{CH}_3$, $\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{13}C NMR (101 MHz, CDCl_3) δ 153.2 (C=O), 148.4, 148.3 ($\text{C}^{\text{q,Ar}}$), 143.1 ($\text{C}^{\text{q,Ar}}$), 135.2, 135.0 ($\text{C}^{\text{q,Ar}}$), 128.8 (CH^{Ar}), 127.9 (CH=C), 125.6 (CH^{Ar}), 118.9 (CH=C), 118.8 (CH^{Ar}), 84.4 (O- CH_2 -O), 73.2 ($\text{CH}(\text{CH}_3)_2$), 71.2 ($\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 66.4 (C^{c}), 63.6 (C^{a}), 57.8 (CH_2 -N), 35.7 (Ar- $\text{CH}_2(\text{CH}_2)_3\text{CH}_3$), 31.9, 31.5, 31.1, 30.8, 30.7 (C^{b}), 29.8, 29.7, 29.6, 29.5, 29.4, 26.2 (CH_2 -P), 22.7, 22.5, 21.6, 21.5 ($\text{CH}(\text{CH}_3)_2$), 14.3, 14.2 (C=C CH_3), 14.1 ($\text{CH}_3(\text{CH}_2)_{15}\text{O}$), 14.0 (Ar- $(\text{CH}_2)_4\text{CH}_3$). ^{31}P NMR (162 MHz, CDCl_3) δ 27.56. HRMS (ESI): m/z [$\text{M}+\text{Na}$] $^+$ calcd for $\text{C}_{42}\text{H}_{72}\text{N}_3\text{NaO}_7\text{P}$: 784.500009, found: 784.499917.

[3-Hexadecyloxypropoxy-[(*E*)-3-methyl-4-[4-(heptylphenyl)triazol-1-yl]but-2-enyl]phosphoryl]oxymethyl isopropyl carbonate (**15e**)

The title compound was prepared from **14** (113 mg, 0.19 mmol) and 1-ethynyl-4-heptylbenzene (56 μ L, 0.25 mmol) following the general procedure B; the resulting suspension was stirred for 2 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 4/6), the desired pure compound **15e** (118 mg, 78%) was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.73 (t, $J = 3.9$ Hz, 3H, H^{Ar} , H^5), 7.22 (d, $J = 8.0$ Hz, 2H, H^{Ar}), 5.70–5.60 (m, 3H, O- CH_2 -O; 1H, CH=C), 4.94 (s, 2H, CH_2 -N), 4.89 (sept., $J = 6.3$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 4.20–4.11 (m, 2H, H^{a}), 3.43 (t, $J = 6.1$ Hz, 2H, H^{c}), 3.35 (t, $J = 6.7$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2$ -O), 2.73 (dd, $J = 22.8, 7.8$ Hz, 2H, CH_2 -P), 2.63 (t, $J = 7.8$ Hz, 2H, Ar- $\text{CH}_2(\text{CH}_2)_5\text{CH}_3$), 1.90 (quint., $J = 6.3$ Hz, 2H, H^{b}), 1.65 (d, $J = 4.1$ Hz, 3H, C=C CH_3), 1.60 (quint., $J = 7.2$, Ar- $\text{CH}_2\text{CH}_2(\text{CH}_2)_4\text{CH}_3$), 1.52 (quint., $J = 7.0$ Hz, 2H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O), 1.29–1.25 (m, 40H, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2$ -O, $\text{CH}(\text{CH}_3)_2$, Ar- $\text{CH}_2\text{CH}_2(\text{CH}_2)_4\text{CH}_3$), 0.93 (t, $J = 7.3$ Hz, 3H, Ar- $(\text{CH}_2)_6\text{CH}_3$), 0.88 (t, $J = 6.7$ Hz, 3H, $\text{CH}_3(\text{CH}_2)_{15}\text{O}$). ^{13}C NMR (101 MHz, CDCl_3) δ 153.3 (C=O), 143.5 ($\text{C}^{\text{q,Ar}}$), 135.2 ($\text{C}^{\text{q,Ar}}$), 135.1 ($\text{C}^{\text{q,Ar}}$), 129.5, 129.3 (CH^{Ar}), 128.8 (CH^{Ar}), 127.9 (CH=C), 125.6 (CH^{Ar}), 118.9 (CH=C), 84.5, 84.4 (O- CH_2 -O), 73.3 ($\text{CH}(\text{CH}_3)_2$),

71.2 (CH₃(CH₂)₁₄CH₂-O), 66.4 (C^c), 63.6, 63.5 (C^a), 57.8 (CH₂-N), 35.4 (Ar-CH₂(CH₂)₅CH₃), 33.5, 32.0, 31.4, 30.8, 30.7 (C^b), 30.2, 29.7, 29.7, 29.6, 29.6, 29.5, 29.4, 27.6, 26.2 (CH₂-P), 22.7, 22.3, 21.6, 21.6 (CH(CH₃)₂), 14.3 (C=CCH₃), 14.1 (CH₃(CH₂)₁₅O), 13.9 (Ar-(CH₂)₆CH₃). ³¹P NMR (162 MHz, CDCl₃) δ 27.49. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₄₄H₇₇N₃O₇P: 790.549365, found: 790.549322.

[[*(E)*-4-(4-Carbamoyl-1H-1,2,3-triazol-1-yl)-3-methyl-but-2-enyl]-[3-hexadecyloxypropoxy]phosphoryloxymethyl isopropyl carbonate (**15j**)

The title compound was prepared from **14** (166 mg, 0.28 mmol) and propiolamide (25 mg, 0.37 mmol) following the general procedure B; the resulting suspension was stirred for 18 h at 40 °C. After purification on a silica gel column chromatography (MeOH/CH₂Cl₂, 3/97), the desired pure compound **15j** (130 mg, 70%) was obtained as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (s, 1H, H⁵), 7.05 (s, 1H, NH₂), 5.76 (s, 1H, NH₂), 5.69–5.58 (m, 2H, O-CH₂-O; 1H, CH=C), 4.94–4.91 (m, 2H, CH₂-N; 1H, CH(CH₃)₂), 4.22–4.12 (m, 2H, H^a), 3.46 (t, *J* = 6.1 Hz, 2H, H^c), 3.37 (t, *J* = 6.7 Hz, 2H, CH₃(CH₂)₁₄CH₂-O), 2.71 (dd, *J* = 22.9, 7.8 Hz, 2H, CH₂-P), 1.90 (quint., *J* = 6.3 Hz, 2H, H^b), 1.62 (d, *J* = 4.4 Hz, 3H, C=CCH₃), 1.52 (quint., *J* = 7.0 Hz, 2H, CH₃(CH₂)₁₃CH₂CH₂-O), 1.31–1.24 (m, 32H, CH₃(CH₂)₁₃CH₂CH₂-O, CH(CH₃)₂), 0.87 (t, *J* = 7.0 Hz, 3H, CH₃(CH₂)₁₅O). ¹³C NMR (101 MHz, CDCl₃) δ 161.8 (NH₂C=O), 153.2 (C=O), 143.1 (C^{q,Ar}), 134.2, 134.1 (CH=C), 125.6 (CH^{Ar}), 120.1, 120.0 (CH=C), 84.5, 84.4 (O-CH₂-O), 73.2 (CH(CH₃)₂), 71.3 (CH₃(CH₂)₁₄CH₂-O), 66.4 (C^c), 63.6, 63.5 (C^a), 58.2, 58.1 (CH₂-N), 31.9, 30.8, 30.7 (C^b), 29.7, 29.6, 29.6, 29.6, 29.5, 29.3, 27.6, 26.2, 26.1 (CH₂-P), 22.7, 21.6 (CH(CH₃)₂), 14.3, 14.2 (C=CCH₃), 14.1 (CH₃(CH₂)₁₅O). ³¹P NMR (162 MHz, CDCl₃) δ 27.11. HRMS (ESI): *m/z* [M+H]⁺ calcd for C₃₂H₆₀N₄O₈P: 659.414328, found: 659.414346.

[3-Hexadecyloxypropoxy]-[*(E)*-3-methyl-4-[4-(nitrophenyl)triazol-1-yl]but-2-enyl]phosphoryloxymethyl isopropyl carbonate (**15l**)

The title compound was prepared from **14** (115 mg, 0.20 mmol) and 1-ethynyl-4-nitrobenzene (37 mg, 0.25 mmol) following the general procedure B; the resulting suspension was stirred for 3 h at 40 °C. After purification on a silica gel column chromatography (EtOAc/PE, 5/5), the desired pure compound **15l** (102 mg, 71%) was obtained as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.8 Hz, 2H, H^{Ar}), 8.01 (d, *J* = 8.9 Hz, 2H, H^{Ar}), 7.98 (s, 1H, H⁵), 5.70–5.58 (m, 3H, O-CH₂-O; 1H, CH=C), 4.97 (s, 2H, CH₂-N), 4.89 (sept., *J* = 6.3 Hz, 1H, CH(CH₃)₂), 4.22–4.11 (m, 2H, H^a), 3.44 (t, *J* = 6.2 Hz, 2H, H^c), 3.35 (t, *J* = 6.6 Hz, 2H, CH₃(CH₂)₁₄CH₂-O), 2.73 (dd, *J* = 22.8, 7.8 Hz, 2H, CH₂-P), 1.90 (quint., *J* = 6.2 Hz, 2H, H^b), 1.66 (d, *J* = 4.4 Hz, 3H, C=CCH₃), 1.52 (quint., *J* = 7.0 Hz, 2H, CH₃(CH₂)₁₃CH₂CH₂-O), 1.27–1.23 (m, 32H, CH₃(CH₂)₁₃CH₂CH₂-O, CH(CH₃)₂), 0.86 (t, *J* = 7.0 Hz, 3H, CH₃(CH₂)₁₅O). ¹³C NMR (101 MHz, CDCl₃) δ 153.2 (C=O), 147.3 (C^{q,Ar}), 146.0 (C^{q,Ar}), 136.9 (C^{q,Ar}), 134.7, 134.5 (CH=C), 126.1 (CH^{Ar}), 124.3 (CH^{Ar}), 121.0 (CH^{Ar}), 119.8, 119.7 (CH=C), 84.4, 84.3 (O-CH₂-O), 73.3, 73.1 (CH(CH₃)₂), 71.2 (CH₃(CH₂)₁₄CH₂-O), 66.5, 66.3 (C^c), 63.6, 63.5 (C^a), 58.1, 58.0 (CH₂-N), 31.9, 30.8, 30.7 (C^b), 29.7, 29.6, 29.6, 29.6, 29.5, 29.5, 29.3, 27.5, 26.1, 26.1 (CH₂-P), 22.7, 21.6, 21.6, 21.6 (CH(CH₃)₂), 14.4, 14.3 (C=CCH₃), 14.1 (CH₃(CH₂)₁₅O). ³¹P NMR (162 MHz, CDCl₃) δ 27.31. HRMS (ESI): *m/z* [M+Na]⁺ calcd for C₃₇H₆₁N₄NaO₉P: 759.406837, found: 759.406817.

4. Conclusions

In summary, we have efficiently synthesized various hitherto unknown ANP prodrugs bearing the (*E*)-2'-methyl-but-2'-enyl aliphatic side-chain with 1,4-substituted-1,2,3-triazoles as nucleobase. The convergent synthesis was based on olefin acyclic cross-metathesis and CuAAC cross-coupling reaction as the key steps. All those compounds were evaluated against HBV, HIV and SARS-CoV-2 viruses for their antiviral properties. Among them, compound **15j**, a HDP/POC prodrug with R = C(O)NH₂, a ribavirin analog, showed 62% inhibition (at 10 μM) without significant cytotoxicity (IC₅₀ 66.4 μM in HepG2 cells and IC₅₀ = 43.1 μM in HepG2 cells). Further structural optimization of both the (*E*)-2'-methyl-but-2'-enyl aliphatic side-chain and the heterocycle is underway, alongside more detailed

biological testing of the most active compound, with the aim of improving further its antiviral potency.

Supplementary Materials: The following are available online at <https://www.mdpi.com/1420-3049/26/5/1493/s1>, ¹H-, ¹³C-, ³¹P- and NOESY NMR spectra of all synthesized molecules.

Author Contributions: Conceptualization, V.R. and L.A.A.; chemistry of all compounds, T.A.; biological evaluation on HBV, J.M., C.G.-G., D.B., T.R.M. and R.F.S.; biological evaluation on SARS-CoV-2, C.B., F.T., B.C.; writing—original draft preparation, T.A., V.R., L.A.A.; supervision, L.A.A. and V.R. All authors have read and agreed to the published version of the manuscript.

Funding: T. Abuduaini thanks the China Scholarship Council for the PhD fellowship. We thank L. Bassit and O. Russell (from Pr. Raymond F. Schinazi's laboratory) for the biological evaluations. R.F.S. is supported in part by NIH grant P30AI050409. L.A.A. thanks the LABEX SynOrg (ANR-11-LABX-0029) for support.

Conflicts of Interest: No potential conflict of interest was reported by the authors.

Sample Availability: Samples of the compounds are available on request from the corresponding authors.

References

1. Krečmerová, M. Nucleoside and nucleotide analogues for the treatment of herpesvirus infections: Current stage and new prospects in the field of acyclic nucleoside phosphonates. In *Herpesviridae—A Look into This Unique Family of Viruses*; Magel, F.D., Ed.; IntechOpen Limited: London, UK, 2012; pp. 245–270, ISBN 978-953-51-0186-4.
2. Holý, A. *Current Protocols in Nucleic Acid Chemistry*; Synthesis of acyclic nucleoside phosphonates. Unit 14.2; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2005.
3. De Clercq, E.; Holý, A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. *Nat. Rev. Drug Discov.* **2005**, *4*, 928–940. [[CrossRef](#)] [[PubMed](#)]
4. De Clercq, E. Acyclic nucleoside phosphonates: An unfinished story. *Collect. Czech. Chem. Commun.* **2011**, *76*, 480–506. [[CrossRef](#)]
5. Wiemer, A.J.; Wiemer, D.F. Prodrugs of phosphonates and phosphates: Crossing the membrane barrier. *Top. Curr. Chem.* **2015**, *360*, 115–160.
6. Farquhar, D.; Srivastva, D.N.; Kattesch, N.J.; Saunders, P.P. Biologically reversible phosphate-protective groups. *J. Pharm. Sci.* **1983**, *72*, 324–325. [[CrossRef](#)] [[PubMed](#)]
7. Srivastva, D.N.; Farquhar, D. Bioreversible phosphate protective groups—Synthesis and stability of model acyloxymethyl phosphates. *Bioorg. Chem.* **1984**, *12*, 118–129. [[CrossRef](#)]
8. Naesens, L.; Bischofberger, N.; Augustijns, P.; Annaert, P.; Van den Mooter, G.; Arimilli, M.N.; Kim, C.U.; De Clercq, E. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropoxyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. *Antimicrob. Agents Chemother.* **1998**, *42*, 1568–1573. [[CrossRef](#)]
9. Hostetler, K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. *Antiviral. Res.* **2009**, *82*, A84–A98. [[CrossRef](#)]
10. Ballatore, C.; McGuigan, C.; De Clercq, E.; Balzarini, J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1053–1056. [[CrossRef](#)]
11. McGuigan, C.; Hassan-Abdallah, A.; Srinivasan, S.; Wang, Y.; Siddiqui, A.; Daluge, S.M.; Gudmundsson, K.S.; Zhou, H.; McLean, E.W.; Peckham, J.P.; et al. Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. *J. Med. Chem.* **2006**, *49*, 7215–7226. [[CrossRef](#)]
12. Topalis, D.; Pradère, U.; Roy, V.; Caillat, C.; Azouzi, A.; Broggi, J.; Snoeck, R.; Andrei, G.; Lin, J.; Eriksson, S.; et al. Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. *J. Med. Chem.* **2011**, *54*, 222–232. [[CrossRef](#)]
13. Montagu, A.; Pradère, U.; Roy, V.; Nolan, S.P.; Agrofoglio, L.A. Expedient convergent procedure for the preparation of bis(POC) prodrugs of new (E)-4-phosphono-but-2-en-1-yl nucleosides. *Tetrahedron* **2011**, *67*, 5319–5328. [[CrossRef](#)]
14. Pradère, U.; Clavier, H.; Roy, V.; Nolan, S.P.; Agrofoglio, L.A. The shortest strategy for generating phosphonate prodrugs by olefin cross metathesis—application to acyclonucleoside phosphonates. *Eur. J. Org. Chem.* **2011**, *36*, 7324–7330. [[CrossRef](#)]
15. Hamada, M.; Roy, V.; McBrayer, T.R.; Whitaker, T.; Urbina-Blanco, C.; Nolan, S.P.; Balzarini, J.; Snoeck, R.; Andrei, G.; Schinazi, R.F.; et al. Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides. *Eur. J. Med. Chem.* **2013**, *67*, 398–408. [[CrossRef](#)]
16. Amblard, F.; Cho, J.H.; Schinazi, R.F. The Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide and oligonucleotide chemistry. *Chem. Rev.* **2009**, *109*, 4207–4220. [[CrossRef](#)] [[PubMed](#)]
17. Bessièrès, M.; Hervin, V.; Roy, V.; Chartier, A.; Snoeck, R.; Andrei, G.; Lohier, J.-F.; Agrofoglio, L.A. Highly convergent synthesis and antiviral activity of ϵ -but-2-enyl nucleoside phosphonoamidates. *Eur. J. Med. Chem.* **2018**, *25*, 678–686. [[CrossRef](#)] [[PubMed](#)]
18. Tornøe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regioselective copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J. Org. Chem.* **2002**, *67*, 3057–3064. [[CrossRef](#)] [[PubMed](#)]

19. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A Stepwise Huisgen Cycloaddition Process: Copper(I)—Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. *Angew. Chem. Int. Ed.* **2002**, *41*, 2565–2568. [[CrossRef](#)]
20. Zheng, H.; McDonald, R.; Hall, D.G. Boronic acid catalysis for mild and selective [3+2] dipolar cycloadditions to unsaturated carboxylic acids. *Chem. Eur. J.* **2010**, *16*, 5454–5460. [[CrossRef](#)]
21. Langley, D.R.; Walsh, A.W.; Baldick, C.J.; Eggers, B.J.; Rose, R.E.; Levine, S.M.; Kapur, J.; Colonna, R.J.; Tenney, D.J. Inhibition of hepatitis B virus polymerase by entecavir. *J. Virol.* **2007**, *81*, 3992–4001. [[CrossRef](#)] [[PubMed](#)]
22. Marlet, J.; Lier, C.; Roch, E.; Maugey, M.; Moreau, A.; Combe, B.; Lefeuvre, S.; d’Alteroche, L.; Barbereau, D.; Causse, X.; et al. Revisiting HBV resistance to entecavir with a phenotypic approach. *Antiviral Res.* **2020**, *181*, 104869. [[CrossRef](#)]
23. Ladner, S.K.; Otto, M.J.; Barker, C.S.; Zaifert, K.; Wang, G.H.; Guo, J.T.; Seeger, C.; King, R.W. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication. *Antimicrob. Agents Chemother.* **1997**, *41*, 1715–1720. [[CrossRef](#)]
24. Stuyver, L.J.; Lostia, S.; Adams, M.; Mathew, J.S.; Pai, B.S.; Grier, J.; Tharnish, P.M.; Choi, Y.; Chong, Y.; Choo, H.; et al. Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. *Antimicrob. Agents Chemother.* **2002**, *46*, 3854–3860. [[CrossRef](#)] [[PubMed](#)]
25. Schinazi, R.F.; Sommadossi, J.P.; Saalman, V.; Cannon, D.L.; Xie, M.-W.; Hart, G.C.; Smith, G.A.; Hahn, E.F. Activity of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. *Antimicrob. Agents Chemother.* **1990**, *34*, 1061–1067. [[CrossRef](#)]
26. Schinazi, R.F.; McMillan, A.; Cannon, D.; Mathis, R.; Lloyd, R.M.; Peck, A.; Sommadossi, J.-P.; St Clair, M.; Wilson, J.; Furman, P.A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of *cis*-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. *Antimicrob. Agents Chemother.* **1992**, *36*, 2423–2431. [[CrossRef](#)] [[PubMed](#)]
27. Belen'kii, M.S.; Schinazi, R.F. Multiple drug effect analysis with confidence interval. *Antivir. Res.* **1994**, *25*, 1–11. [[CrossRef](#)]
28. Chou, T.-C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul.* **1984**, *22*, 27–55. [[CrossRef](#)]